Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | BAZ2B | Q9UIF8 | 3/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13834486 | 0.89 | CYP3A4 (0.41) | CYP3A4SIRT2SIRT1HTR6HDAC1 | |
| SCHEMBL12479898 | 0.87 | CYP3A4 (0.43) | CYP3A4SIRT2SIRT1HTR6BAZ2B | |
| SCHEMBL16638434 | 0.85 | PTGS1 (0.44) | HTR6BAZ2BHDAC1HDAC6MAPT | |
| SCHEMBL12480356 | 0.84 | CYP3A4 (0.35) | CYP3A4SIRT2SIRT1HDAC1HDAC6 | |
| SCHEMBL166839 | 0.82 | HTR6 (0.53) | HTR6BAZ2BHTR2AHTR2CHDAC1 | |
| SCHEMBL13833885 | 0.78 | SIRT2 (0.45) | CYP3A4SIRT2SIRT1HTR6HTR2A | |
| SCHEMBL12479756 | 0.78 | CYP3A4 (0.45) | CYP3A4SIRT2SIRT1HTR6HDAC1 | |
| SCHEMBL12479950 | 0.78 | CNR1 (0.47) | HTR6BAZ2BHDAC1HDAC6 | |
| SCHEMBL2193338 | 0.77 | BAZ2B (0.36) | HTR6BAZ2BHDAC1HDAC6MAPT | |
| SCHEMBL13833898 | 0.76 | SIRT2 (0.38) | CYP3A4SIRT2SIRT1HTR6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20150266884-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150266884-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150266884-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2015-09-24 | — | — | US | disclosed |
| US-9006263-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20130190294-A1 | COMPOUNDS AND METHODS FOR TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053367-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053367-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053367-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| WO-2012154261-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012154261-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012112966-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | CYP3A4 720/4885SIRT2 1447/4885SIRT1 2145/4885 |
| US-20130190294-A1 | COMPOUNDS AND METHODS FOR TREATING DIABETES | ADRB2, ADRA2B, ADRA2C | CYP3A4 964/4885SIRT2 729/4885SIRT1 2207/4885 |
| US-20150266884-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | CYP3A4 720/4885SIRT2 1447/4885SIRT1 2145/4885 |
| US-20130053367-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | ADRB2, ADRA2B, ADRA2C | CYP3A4 903/4885SIRT2 738/4885SIRT1 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.